Frova
Product Images NDC 16590-396

4 FDA label images from Stat Rx Usa Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Frova (NDC 16590-396). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Stat Rx Usa Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Frova 2.5mg Label Image (Frova 2.5mg Label)

Frova 2.5mg Label Image (Frova 2.5mg Label)
FROVA 2.5 mg tablet packaging label from STAT RX USA LLC. The label indicates the product contains 9 tablets, each with 3.91 mg of frovatriptan succinate equivalent to 2.5 mg frovatriptan. Manufactured by Endo Pharmaceuticals Inc. in Chadds Ford, PA. It includes lot information, NDC number 16590-396-09, storage instructions, and a caution to see the package insert.*
FDA Label Image

Frovatriptan Succinate Chemical Structure (Frova Figure 1)

Frovatriptan Succinate Chemical Structure (Frova Figure 1)
Chemical structure diagram of the active ingredient in FROVA by STAT RX USA LLC, showing molecular connectivity and functional groups clearly depicted.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving Initial Headache Response Within 2 Hours (Frova Figure 2)

Figure 1: Estimated Probability Of Achieving Initial Headache Response Within 2 Hours (Frova Figure 2)
A line graph comparing the estimated probability of response over time (up to 2 hours) after initial dosing between FROVA 2.5 mg and placebo. The graph shows FROVA 2.5 mg with a consistently higher probability of response compared to placebo throughout the 2-hour period.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment (Frova Figure 3)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Or Other Medication For Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment (Frova Figure 3)
A line graph comparing the estimated probability of medication or rescue use over 24 hours after an initial dose of FROVA 2.5 mg versus placebo. The x-axis shows time in hours, and the y-axis shows the probability percentage, with FROVA showing a lower probability compared to placebo throughout the 24-hour period.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.